Figure 2.
Cutaneous leishmaniasis drug discovery scheme. MTA = material transfer agreement; T.I. = therapeutics initiative; i.p. = intraperitoneal; MLS = mouse leishmaniasis suppression; ID, identification; MLL = mouse leishmaniasis lesion; p.o. = per os; PK = pharmacokinetics; IVMN = in vitro micronucleus assay; hERG = human ether-à-go-go–related gene; DDI = drug-drug interaction; SAR = structure activity relationship.